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EFFECT OF BODY COMPOSITION AND RENAL FUNCTION ON THE PHAR-
MACOKINETICS OF HIGH-DOSE MELPHALAN FOR MULTIPLE MYELOMA
Vogl, D.T.1, Mick, R.2, Stoopler, E.3, Davis, L.E.4, Paul, T.M.1,
Salazar, G.5, Raguza-Lopez, M.1, Porter, D.L.1, Luger, S.M.1,
Stadtmauer, E.A.1 1Abramson Cancer Center, University of Pennsylva-
nia, Philadelphia; 2University of Pennsylvania, Philadelphia; 3University
of Pennsylvania School of Dental Medicine, Philadelphia; 4University of
the Sciences, Philadelphia; 5University of Puerto Rico, San Juan
Background:High dosemelphalan is themost common regimen for
autologous stem cell transplantation (ASCT) for multiple myeloma
(MM), but toxicity and efficacy are variable. We hypothesized that
variation in body size, body composition, and renal function would
explain differences in melphalan pharmacokinetics and therefore in
outcomes after transplant.
Methods: We evaluated 41 patients who received melphalan 200
mg/m2 on day -2 (one patient with poor renal function received
180mg/m2).We calculatedmelphalan doses using ideal body weight
(IBW), using adjusted IBW (ABW) for patients weighing.120% of
IBW.Wemeasured body composition using dual x-ray absorptiom-
etry (DEXA), renal function with both iohexol clearance (Cliohexol)
and the Cockroft-Gault formula (CrClCG), and plasma melphalan
concentrations using HPLC/tandem mass spectrometry. We used
non-compartmental analysis to estimate melphalan clearance
(ClMEL) and area under the curve (AUCMEL) and linear regression
modeling to identify factors associated with melphalan pharmacoki-
netics.
Results: Patients’ mean BSA using actual weight was 1.93 m2 (range
1.44-2.48). By DEXA scan, the mean lean body weight was 53.3 kg
(SD 11.0) and mean fat percentage 31% (SD 9.5%). Mean iohexol
clearance was 109 mL/min (range 28-163). AUCMEL varied signifi-
cantly, with a range of 7.6-26.6 mg*h/L (mean 13.6, SD 3.8); ClMEL
was similarly variable (mean 27.9mL/min, SD 8.1). In univariate anal-
yses, ClMEL was inversely related to age and directly related to weight,
BSA, lean body weight, bone mineral content, Cliohexol, CrClCG, and
MEL dose. ClMEL was not associated with body fat percentage,
body fat weight, or body lean percentage, or with othermeasurements,
such as hemoglobin, albumin, immunoglobulins, or M-spike. The
strongest correlation with ClMEL was for CrClCG, and multivariable
models showed no improved prediction of ClMEL with the addition
of other factors to CrClCG. The best model for predicting AUCMEL
was dose/CrClCG (see table). These models consistently under-pre-
dicted AUCMEL (mean prediction error -3.3% to -2.6%).
Table. Performance of linear models predicting AUCMEL
Model R2 p-valuedose/CrClCG 0.26 0.001
dose/Cliohexol 0.11 0.04
dose/weight 0.10 0.04
dose/lean weight 0.08 0.08
dose/BSAIBW 0.06 0.11
dose/BSAABW 0.04 0.23Conclusion:A composite calculation incorporating age, weight, and
serum creatinine, like CrClCG, may be the best way to choose mel-
phalan doses but only explains 26% of drug exposure variability.
Other measures of body composition were poor predictors of expo-
sure. Further research is needed to better address the remaining var-
iability in drug clearance and exposure.120
COMPARATIVE COST UTILITY ANALYSIS OF PLERIXAFOR PLUS GCSF
VERSUS CYCLOPHOSPHAMIDE PLUS GCSF AS SALVAGE MOBILIZATION
REGIMENS IN MULTIPLE MYELOMA PATIENTS
Tuffaha, H.W.1, Hussein, A.A.2, Abdel-Rahman, F.A.2 1King Hussein
Cancer Center, Amman, Jordan; 2King Hussein Cancer Center, Amman,
Jordan
Introduction: Plerixafor is a novel agent that enhances the mobili-
zation of peripheral blood stem cells (PBSCs) in lymphoma andmul-tiple myeloma (MM) patients whose cells mobilize poorly. Due to
the substantial cost associated with its use, a cost utility analysis
was performed to evaluate the economics of salvage Plerixafor in
MM patients who failed previous mobilization.
Methods: A decisionmodel was developed to analyze the cost utility
for two salvage regimens: Plerixafor + GCSF (PG) versus Cyclo-
phosphamide + GCSF (CG). The model assumes that patients un-
dergo mobilization with one of the regimens, followed by
apheresis and subsequent autologous transplant if CD34+ cell count
is $ 2 x 106 cells/kg, or Bortezomib plus Dexamethasone if insuffi-
cient CD34+ cells are collected. Patients included in the model
will eventually progress and die from their disease. A structured lit-
erature review was performed to collect data on the successful mobi-
lization rate, life year gained and quality of life associated with the
modeled options. The analysis was from the perspective of Jordanian
Ministry of Health; the costs were based on its list prices and in-
cluded the costs of medications, apheresis, autologous transplant
and adverse effects management. The willingness to pay threshold
was $30,000 per quality adjusted life year (QALY). Incremental
cost effectiveness ratio (ICER) was calculated by dividing the incre-
mental average cost by the incremental QALY gained. One-way sen-
sitivity analysis was performed to explore the impact of the
uncertainty in efficacy data on the results.
Results: The model showed that PG was associated with higher
probability of achieving successful re-mobilization and subsequent
transplant. The average total costs associated with CG and PG
were $41,500 and $58,400 respectively. The estimated ICER was
$52,813/QALY. (Table 1) The sensitivity analysis revealed that the
ICERs ranged from $86,500 to $40,488 per QALY gained when the
probability of PG success ranged from 60% to 95%.
Conclusion: This analysis showed that the use of Plerixafor plus
GCSF as salvage mobilization regimen in MM patients was not
cost effective compared to Cyclophosphamide plus GCSF from
the perspective of our health care system. To our knowledge, this
is the first study to describe a cost utility analysis of Plerixafor use
in this indication.
Table 1. Analysis of Plerixafor plus GCSF (PG) versus Cyclo-
phosphamide plus GCSF (CG)
Incremental
Regimen PG CG resultsProbability of successful
mobilization0.80 0.27 0.53Average total costs $58,400 $41,500 $16,900
Life year gained 4.3 3.8 0.50
QALY 2.58 2.26 0.32
ICER ($/QALY gained)
for PG$52,813121
OUTCOME OF PATIENTS WITH NONSECRETORY MULTIPLE MYELOMA
AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Farhan, S., Lin, H., Baladandayuthapani, V., Shah, N., Bashir, Q.,
Hosing, C., Popat, U., Parmar, S., Dinh, Y., Qureshi, S., Rondon, G.,
Giralt, S., Champlin, R., Qazilbash, M. The University of Texas MD
Anderson Cancer Center, Houston, TX
Background: More than 95% of patients with multiple myeloma
have a detectable monoclonal protein either in the serum or urine.
Less than 5% of patients have non-secertory myeloma (NSM), char-
acterized by the absence of a monoclonal protein. There are limited
available data on the outcome of patients withNSM (Ref. Kumar S et
al.). We studied the outcomes of patients with NSM after high-dose
chemotherapy and autologous hematopoietic stem cell transplanta-
tion (auto-HCT), and compared them to a matched group of pa-
tients with secretory myeloma (SM).
Methods: Between 1988 and December 2010, 1567 patients with
MMreceived auto-HCTat our institution.We identified 31 patients
with NSM and compared their outcome to a matched group of 94
patients with SM. Patients were matched for age at auto-HCT,
Durie-Salmon stage, response to therapy prior to auto-HCT, and
the year of auto-HCT. Variables for the two groups were compared
using the conditional logistic regression method to adjust the
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sion (TTP), progression-free survival (PFS), and overall survival
(OS), all defined from the time of auto-HCT. Stratified Log-rank
test and Cox proportional hazards model stratified on matched pairs
were conducted on TTP, PFS and OS.
Results: Patient characteristics are summarized in the attached
Table. NSM and SM groups were not different by age at auto-
HCT, time from diagnosis to auto-HCT, race, sex, and serum
creatinine at auto-HCT (Table). Patients with SM had higher
percentage of bone marrow plasma cells at auto-HCT. Median
follow-up time was 37 months. Median TTP was 29 months and
31 months for the NSM and SM groups, respectively. Median
PFS was 16 months and 29 months for the NSM and SM groups,
respectively. Median OS was 45 and 67 months in the NSM and
SM groups, respectively. There was no difference in TTP, PFS
and OS between NSM and SM after adjusting for conditioning
regimen or time from diagnosis to transplant in the multivariate
models (p-Value .0.69).
Conclusion: In this large single center study the outcome of pa-
tients with NSM was comparable to patients with SM after an
auto-HCT.
Table. Association between patients characteristics and
histology
Covariate Levels NSM SM p-ValueAge at diagnosis age< 5 54.25 (median) 17 (54.8%) 45 (47.9%) 0.478age>54.25 14 (45.2%) 49 (52.1%)Age at transplant age < 5 55.17(median) 17 (54.8%) 45 (47.9%) 0.4625age >55.17 14 (45.2%) 49 (52.1%)Age at transplant <40 1 (3.2%) 2 (2.1%) 0.807240-49 7 (22.6%) 24 (25.5%)50-59 16 (51.6%) 48 (51.1%)> 5 60 7 (22.6%) 20 (21.3%)Time from diagnosis
to transplant>8months 12 (38.7%) 43 (45.7%) 0.2863< 5 8 months 19 (61.3%) 51 (54.3%)Racial Group Black 3 (9.7%) 11 (12%) 0.2849Mixed 4 (12.9%) 25 (27.2%)White 24 (77.4%) 56 (60.9%)Sex F 14 (45.2%) 34 (36.2%) 0.3010M 17 (54.8%) 60 (63.8%)Plasmacytoma No 24 (77.4%) 70 (75.3%) 0.7646Yes 7 (22.6%) 23 (24.7%)Creatinine < 5 1 13 (52%) 36 (48%) 0.3242>1 12 (48%) 39 (52%)Plasma cell%
pre-transplant< 5 10% 9 (34.6%) 14 (17.5%) 0.0561>10% 17 (65.4%) 66 (82.5%)122
PEGFILGRASTIM VS FILGRASTIM-BASED STEADY STATE AUTOLOGOUS
HSC MOBILIZATION IN THE SETTING OF PATIENT ADAPTED (‘‘JUST IN
TIME’’) PLERIXAFOR: EFFICACY AND ECONOMIC OUTCOMES
Costa, L.J., Kramer, C., Hogan, K.R., Butcher, C.D., Littleton, A.,
Shoptaw, K.B., Kang, Y., Stuart, R.K. Medical University of South Car-
olina, Charleston, SC
Plerixafor enhances the ability of filgrastim to mobilize CD34+
cells for AHSCT in patients with lymphoma (LY) or multiple my-
eloma (MM). Single dose of pegfilgrastim has, in some series,
been utilized for autologous mobilization for its convenience
and possibly greater efficacy. We retrospectively compared two
consecutive mobilization cohorts utilizing filgrastim (FIL) 10
mcg/kg/day or pegfilgrastim (PEG) 12 mg (single dose) for steady
state mobilization and the same algorithm for ‘‘just in time’’ use of
plerixafor. In both cohorts peripheral blood CD34+ cells (PB-
CD34+) enumeration was performed on the 4th day after initia-
tion of growth factor to determine the immediate initiation of
apheresis or administration of plerixafor with apheresis starting
in the next day. Decision to use plerixafor was determined by
the same previously validated algorithm in both cohorts. Apheresis
and growth factor +/- plerixafor were continued until the mobili-
zation target was met. Analysis of estimated total cost of mobili-zation utilized average wholesale price (AWP) for drugs and
average charges for apheresis, cryopreservation and laboratory
tests from a representative sample of subjects. Seventy-four con-
secutive subjects were included in FIL and 57 in PEG. The two
cohorts were comparable in terms of age (57.5 vs. 53.7), propor-
tion of patients with diagnosis of MM (63.5% vs.66.7%), propor-
tion of MM patients previously exposed to lenalidomide (63.8%
vs. 50%), average body weight (82.9 vs.84 kg) and average mobi-
lization target (4.5 vs. 5 x 106 CD34+/kg). Overall 68/74 in FIL
and 52/57 patients in PEG met the mobilization target. Median
PB-CD34+ on day 4 was significantly higher in PEG.
Table. Mobilization outcomes
FIL PEGPN 5 74 N 5 57Day 4 PB-CD34+ 18.1 (+/-19.5) 28.7 (+/-27) 0.01
Patients requiring plerixafor 50 (67.5%) 26 (45.6%) 0.01
Number of days of apheresis 1.62 (+/-0.72) 1.68 (+/-0.65) 0.6
Number of injections 13.1 (+/-3.8) 2.7 (+/-0.9) 0.001
Number of CD34+ cells
collected (x10e6/kg)7.26 (+/-3.99) 7.54 (+/-3.52) 0.6Patients meeting
mobilization target68 (91.9%) 52 (91.2%) 1Mobilization failures (<2 x 10e6
CD34+/kg)1 (1.3%) 1 (1.7%) 1Patients in PEG received fewer subcutaneous injections and
were less likely to require administration of plerixafor. Cohorts
had near identical average number of apheresis sessions and com-
parable CD34+ yield. The estimated cost associated with growth
factor was on average US$3,069 higher in PEG, but it was coun-
terbalanced by an estimated $3,546 saving in plerixafor, resulting
in no significant difference in the estimated overall cost of mobi-
lization. Single administration of pegfilgrastim is associated with
better CD34+ mobilization than daily filgrastim in patients with
MM and LY allowing for effective mobilization with less frequent
use of plerixafor. Pegfilgrastin with patient adapted used of plerix-
afor is a reliable, convenient and cost-neutral strategy for AHSC
mobilization.123
HIGH DOSE CHEMOTHERAPY (HDT) WITH BUSULFAN, MELPHALAN AND
TOPOTECAN FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION (ASCT) IN PEDIATRIC PATIENTS (pts) WITH HIGH
RISK SOLID TUMORS
Pawlowska, A.B.1, Wolfson, J.A.1, Cheng, J.2, Sorrell, A.1, Sato, J.1,
Anderson, C.1, Hitt, D.1, Suarez, M.1, Forman, S.J.3, Rosenthal, J.1
1City of Hope, Duarte, CA; 2Southern California Kaiser Permanente
Medical Group, Los Angeles, CA; 3City of Hope, Duarte, CA
The prognosis of pts with high risk solid tumors remains poor de-
spite advances in multimodal and high dose radiation and chemo-
therapy.
HDT followed by ASCT appears to provide survival benefit to
a select group of pts. We hypothesize that patients with chemo-sen-
sitive solid tumors with poor risk features at diagnosis or with recur-
rent metastatic disease will have lower morbidity and improved
survival with a conditioning regimen using a novel combination of
busulfan, melphalan and topotecan (B-M-T) followed by ASCT.
In this pilot study pts received topotecan continuous infusion in
combination with busulfan (pharmacokinetics (PK) based dose ad-
justment) and melphalan. The primary outcome of interest was the
toxicity of combined HDT with B-M-T. Secondary objectives
were to evaluate engraftment, survival and PK of busulfan and top-
otecan. Twenty-two patients aged 2.2-27 years (median 8.8 yrs)
were treated on the B-M-T protocol at City of Hope from 5/2007
to 4/2011. Diagnoses included Ewing sarcoma (n 5 8), neuroblas-
toma (n5 7),Wilms (n5 3), rhadbomyosarcoma (n5 3) andmedul-
loblastoma (n 5 1). Seven pts were in complete remission, while 15
